SEC Tracker
Get the app

Olema Pharmaceuticals OLMA

Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor

Form
8-K
Filed
Period
Importance
Notable
Document
8-K
Exhibit 99.1
Press release
  • Makes a Regulation FD disclosure (7.01)
  • Discloses other events (8.01)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Olema Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Annexon ANNX public float $244M, Jun 30, 2025
  2. DBV Technologies DBVT public float $251M, Jun 30, 2025
  3. Heron Therapeutics HRTX public float $235M, Jun 30, 2025
  4. Corvus Pharmaceuticals CRVS public float $252M, Jun 30, 2025
  5. Verastem VSTM public float $254M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.